Richard Evans
Ophthalmology · San Antonio, TXNPI 1811993017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Biotissue Holdings Inc. at 29.1% of the total.
Across 54 payments — averaging $42.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$667
- Alcon$537
- Novartis$240
- Aerie Pharmaceuticals, Inc.$223
- Johnson & Johnson Surgical Vision, Inc.$114
- AbbVie$105
- plus $404 from 9 others
Across 139 payments — averaging $5012.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$485K
- Ocular Therapeutix, Inc.$103K
- Novartis$61K
- Bausch Health US, LLC$43K
- Kala Pharmaceuticals, Inc.$6K
What the payments were for
- Food & beverage$2,290100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 15 | $667 |
| Alcon | 16 | $537 |
| Novartis | 6 | $240 |
| Aerie Pharmaceuticals, Inc. | 2 | $223 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $114 |
| AbbVie | 2 | $105 |
| Bausch & Lomb Americas Inc. | 1 | $100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $92 |
| Sun Pharmaceutical Industries Inc. | 3 | $54 |
| Carl Zeiss Meditec, Inc. | 1 | $42 |
| Alimera Sciences, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Omeros Corporation | 1 | $20 |
| Thea Pharma Inc. | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$160
- AmnioGraft$160
- AcrySof IQ VIVITY IOL$146
- Rhopressa$125
- Rocklatan$125
- Precision 1$120
- LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE$114
- XIIDRA$109
How this compares
$2,290 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 20 | $8,523 |
| Travoprost | 25 | $5,184 |
| Latanoprost | 114 | $1,372 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $198 |
| Timolol Maleate | 23 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $105 | $8,52320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$1.8M
- Gregory ParkhurstSan Antonio$185K
- James LehmannSan Antonio$162K
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.